A cute respiratory distress syndrome (ARDS) is a life-threatening condition that occurs in 17-26 per 100,000 persons per year in the United States (1). Its mortality rate remains about 40 -50% (2), and survivors may have persistent pulmonary and/or nonpulmonary disability (3). Excessive and protracted systemic inflammation is the pathophysiologic hallmark of pulmonary and extrapulmonary organs dysfunctions in patients with ARDS (4, 5).
cessive and protracted systemic inflammation is the pathophysiologic hallmark of pulmonary and extrapulmonary organs dysfunctions in patients with ARDS (4, 5) .
Short courses of high doses of corticosteroids were the first anti-inflammatory strategies tested in early ARDS, but they did not show evidence of beneficial effect (6, 7) . However, a decade later, prolonged administration of methylprednisolone in patients with unresolving (or late) ARDS was shown to be associated with improvement in lung injury and multiple organ dysfunction syndrome scores and reduced mortality rates (8) . Although this study had clear limitations, including a small sample size and a crossover design, it prompted a renewed interest in the use of corticosteroids. In the same time, a better understanding of the mechanisms of action of corticosteroids and of the key role of impaired hypothalamic-pituitary-adrenal axis and of peripheral tissue resistance to corticosteroids in the pathogenesis of septic shock confirmed the potential great interest of these drugs (9) . We have recently demonstrated that a 7-day treatment with low doses of corticosteroids significantly reduced 28-day mortality rate in septic shock patients with relative adrenal insufficiency (nonresponders to a short corticotropin test) (10) . As a large proportion of patients had ARDS at inclusion, this post hoc analysis investigated the efficacy and safety of this treatment in septic shock-associated early ARDS. Moreover, to better understand and discuss the results, we also performed the same analysis in septic shock patients without ARDS.
METHODS
This was a multiple-center, placebocontrolled, randomized, double-blind study (10) . The protocol was approved by an ethics committee, and written informed consent was obtained from the patients themselves or their relatives (11) . Before randomization, patients underwent a short corticotropin test with tetracosactrin (Synacthène Ciba, RueilMalmaison, France), 250 g intravenously. They were graded as nonresponders when cortisol increase was Յ9 g/dL (250 nmol/L). After randomization, they received either hydrocortisone hemisuccinate (Roussel-Uclaf, Romainville, France), 50 mg intravenously every 6 hrs, and 9-␣-fludrocortisone (Pharmacie Centrale des Hôpitaux, Paris, France), 50 g orally once a day, or their placebos for 7 days.
Patients
Detailed eligibility criteria for the randomized trial have been reported elsewhere (10) . Briefly, patients had to meet the following criteria: a) documented site (or at least strong suspicion) of infection; b) temperature Ͼ38.3°C or Ͻ35.6°C; c) heart rate Ͼ90 beats/min; d) systolic arterial pressure Ͻ90 mm Hg for Ն1 hr despite adequate fluid replacement and Ͼ5 g/kg/min of dopamine or current treatment with epinephrine or norepinephrine; e) urinary output Ͻ0.5 mL/kg for Ն1 hr or PaO 2 /FIO 2 ratio Ͻ280 mm Hg; f) arterial lactate levels Ͼ2 mmol/L; g) need for mechanical ventilation. The short corticotropin test had to be performed before randomization and patients had to be randomized within 8 hrs of the onset of shock.
To be considered with septic shockassociated early ARDS, included patients had to meet the following criteria at inclusion (12) : bilateral infiltrates on chest radiograph, PaO 2 /FIO 2 Ͻ200 mm Hg, and pulmonary artery occlusion pressure Յ18 mm Hg or no clinical evidence of left atrial hypertension.
Variables
We analyzed the following variables at inclusion: age, gender, McCabe classification (13), admission category (medical, emergency surgery, elective surgery), prior or preexisting disease, site of infection, mean arterial pressure, Simplified Acute Physiology Score II (14) , Logistic Organ Dysfunction score (15), PaO 2 /FIO 2 , arterial lactates, cortisol, tidal volume, respiratory rate, FIO 2 , positive endexpiratory pressure, and chest radiograph. PaO 2 /FIO 2 and positive end-expiratory pressure were also recorded twice daily up to day 7. Interleukin (IL)-6 plasma levels (measured blindly at Pasteur Institute, Paris, France, using Quantikine HS enzyme immunoassay kit, R&D Systems, Minneapolis, MN) were measured at baseline, day 2, day 3, day 7, and day 14.
Outcomes
As in the main analysis (10), the primary outcome was the 28-day survival distribution in nonresponders. Secondary end points were 28-day survival distributions in responders and in all patients; day 28, intensive care unit (ICU), and hospital discharge mortality rates; the number of days alive and off the ventilator until day 28, in the two subsets of patients and in all patients; and adverse events.
Statistical Analysis
The analysis was performed with SAS (SAS Institute, Cary, NC). It was conducted similarly in septic shock patients with and without early ARDS. Continuous variables were reported as mean Ϯ SD and compared between groups by Student's t-test. Categorical variables were reported as number of patients (percentages) and compared by chisquare or Fisher's exact tests. Treatment effect on 28-day survival distributions was estimated from Cox's proportional hazards regression models using baseline cortisol, cortisol response, McCabe class, Logistic Organ Dysfunction score, arterial lactates, and PaO 2 /FIO 2 for adjustment (10) . Corresponding hazard ratios (HRs) and 95% confidence intervals (CIs) were reported. Proportionality among event rates in the Cox models was assessed by plot of the log (Ϫlog [survival function]) vs. time. When proportionality assumption was not upheld, only log-rank tests were reported. For 28-day survival distributions, patients alive at day 28 were treated as censored. Treatments effect on day 28 and ICU and hospital mortality rates were estimated from logistic regression or exact logistic regression analysis when appropriate using the same covariates as for the Cox models. Corresponding odds ratios (ORs) and 95% CIs were reported. We computed relative risks (RRs) of death and 95% CIs at day 28 and ICU and hospital discharge. Number of days alive and off the ventilator until day 28 was analyzed by Wilcoxon rank-sum tests. Evolutions with time of PaO 2 /FIO 2 and of IL-6 plasma levels were assessed by nonparametric repeated-measures analysis of variance (Friedman test). Proportional hazards regression models were fitted to examine the association of PaO 2 /FIO 2 and of IL-6 plasma levels with survival adjusted for treatment. The impact of PaO 2 /FIO 2 and of IL-6 plasma levels on mortality was assessed by treating PaO 2 /FIO 2 and IL-6 plasma levels as time-dependent covariates. Both were treated on a log scale because of the nonparametric nature of the data. All reported p values were two-sided.
RESULTS

Participants
Among the 299 septic shock patients enrolled and analyzed in the initial study, 177 met the criteria for ARDS (92 in the placebo group and 85 in the steroid group): 129 (67 in the placebo group and 62 in the steroid group) were graded as nonresponders, whereas 48 (25 in the placebo group and 23 in the steroid group) were graded as responders; 120 did not meet the criteria for ARDS (56 in the placebo group and 64 in the steroid group): 99 (47 in the placebo group and 52 in the steroid group) were graded as nonresponders, whereas 21 (9 in the placebo group and 12 in the steroid group) were graded as responders. Two patients (one nonresponder in the placebo group and one responder in the steroid group) could not be classified in terms of ARDS at inclusion because the results of the chest radiograph were missing. Overall, the two treatment groups were well balanced for general characteristics and for severity of illness in septic shock patients with (Tables 1 and 2 ) and without (Tables  3 and 4) Among responders, there was no evidence for significant difference between the two treatment arms for 28-day survival distribution and day-28, ICU, and hospital mortality rates.
In all patients, the median time to death was 12 days in the placebo group and 16 days in the steroid group (adjusted HR 0.58, 95% CI 0.39 -0.85, p ϭ .005). At day 28, there were 62 of 92 (67%) deaths in the placebo group and 49 of 85 (58%) deaths in the steroid group (RR 0.86, 95% CI 0.67-1.08, p ϭ .180; adjusted OR 0.48, 95% CI 0.23-0.98, p ϭ .043). Similar results were observed on ICU and hospital mortality rates (Table 5) .
Septic Shock Patients Without ARDS. There was no evidence for significant difference between the two treatment arms for 28-day survival distribution and day 28, ICU, and hospital mortality rates in nonresponders, responders, and all patients (Table 6 ).
Days Alive and Off the Ventilator and Evolution of PaO 2 /FIO 2
Septic Shock Patients With ARDS. In nonresponders, the number of days alive and off the ventilator was 2.6 Ϯ 6.6 in the placebo group and 5.7 Ϯ 8.6 in the steroid group (p ϭ .006). PaO 2 /FIO 2 significantly increased over time from baseline to day 7 in both groups, the values being significantly higher in the steroid group than in the placebo group (time effect, p Յ .001; treatment effect, p ϭ .034; time ϫ treatment interaction: p ϭ .721; Fig. 1 
, top panel).
In responders, the number of days alive and off the ventilator was 4.6 Ϯ 7.6 in the placebo group and 2.8 Ϯ 7.5 in the steroid group (p ϭ .218). PaO 2 /FIO 2 significantly and similarly increased over time from baseline to day 7 in both groups (time effect, p ϭ .002; treatment effect, p ϭ .607; time ϫ treatment interaction, p ϭ .602; Fig. 1, middle panel) .
In all patients, the number of days alive and off the ventilator was 3.1 Ϯ 6.9 in the placebo group and 4.9 Ϯ 8.4 in the steroid group (p ϭ .089). PaO 2 /FIO 2 significantly increased over time from baseline to day 7 in both groups, the values being significantly higher in the steroid group than in the placebo group (time effect, p Ͻ .001; treatment effect, p ϭ .019; time ϫ treatment interaction, p ϭ .930; Fig. 1 
, bottom panel).
Septic Shock Patients Without ARDS. Among nonresponders, the number of days alive and off the ventilator was 5.9 Ϯ 8.6 in the placebo group and 4.9 Ϯ 7.8 in the steroid group (p ϭ .706). PaO 2 /FIO 2 significantly and similarly increased over time from baseline to day 7 in both groups (time effect, p Յ .001; treatment effect, p ϭ .711; time ϫ treatment interaction, p ϭ .136; Fig. 2 , top panel). Among responders, there was no evidence for significant difference between the two treatment arms for the number of days alive and off the ventilator (p ϭ .894) and the evolution with time of PaO 2 / FIO 2 (Fig. 2, middle panel) .
Among all patients, the number of days alive and off the ventilator was 5.7 Ϯ 8.5 in the placebo group and 4.9 Ϯ 7.9 in the steroid group (p ϭ .672). PaO 2 /FIO 2 significantly and similarly increased over time from baseline to day 7 in both groups (time effect, p Ͻ .001; treatment effect, p ϭ .617; time ϫ treatment interaction, p ϭ .038; Fig. 2, bottom panel) .
Circulating Cytokine Levels
Septic Shock Patients With ARDS. IL-6 plasma levels were significantly higher in nonresponders (n ϭ 41, median, 3488 pg/mL; interquartile range, 12,308 pg/mL) than in responders (n ϭ 17, median, 896 pg/mL; interquartile range, 1133 pg/mL, p ϭ .009). IL-6 plasma levels were significantly and inversely correlated with cortisol levels at 60 mins after adrenocorticotropic hormone (Spearman correlation coefficient Ϫ0.30, p ϭ .022) and with the maximum adrenocorticotropic hormone-induced increment in cortisol (Ϫ0.45, p Ͻ .001).
In nonresponders, IL-6 plasma levels tended to decrease over time from baseline to day 7 in both groups, the values being significantly lower in the steroid increased the probability of surviving, whereas higher IL-6 plasma levels decreased the probability of surviving.
In responders, IL-6 plasma levels remained roughly similar over time from baseline to day 7 in both groups (Fig. 3 , middle panel) and were not correlated to PaO 2 /FIO 2 .
Among all patients, IL-6 plasma levels tended to decrease over time from baseline to day 7 in both groups, the values being significantly lower in the steroid group than in the placebo group (time effect, p ϭ .059; treatment effect, p Ͻ .001; time ϫ treatment interaction, p ϭ .268; Fig. 3,  bottom panel) . IL-6 plasma levels were not correlated to PaO 2 /FIO 2 . PaO 2 /FIO 2 and IL-6 plasma levels were associated with mortality, showing a positive and a negative effect on survival, respectively (HR 0.08; 95% CI 0.01-0.49, p ϭ .006, and HR 1.88; 95% CI 1.26-2.80, p ϭ .002, respectively).
Septic Shock Patients Without ARDS. In nonresponders, IL-6 plasma levels decreased over time from baseline to day 7 in both groups, the values being significantly lower in the steroid group than in the placebo group (time effect, p ϭ .013; treatment effect, p ϭ .002; time ϫ treatment interaction, p ϭ .164).
In responders, the sample size was too small to perform any statistical analysis. Among all patients, IL-6 plasma levels decreased over time from baseline to day 7 in both groups, the values being significantly lower in the steroid group than in the placebo group (time effect, p Ͻ .001; treatment effect, p Ͻ .001; time ϫ treatment interaction, p ϭ .152).
Adverse Events
There was no significant difference between the two treatment groups on the rates of adverse events possibly related to corticosteroids, such as superinfection, gastrointestinal bleeding, or psychiatric disorders (Table 7) , in septic shock patients with and without early ARDS.
DISCUSSION
This analysis shows that a 7-day treatment with the combination of low doses of hydrocortisone and 9-␣-fludrocortisone significantly improved survival at day 28 and at ICU and hospital discharge and reduced the duration of mechanical ventilation in patients with septic shock- associated early ARDS and a weak cortisol response to corticotropin without inducing serious adverse events. In patients with presumed normal hypothalamic pituitary adrenal axis (responders to the short corticotropin test), there was no evidence for a beneficial or a deleterious effect of this treatment on survival or on the duration of mechanical ventilation. The lack of similar effect of corticosteroids in nonresponders and responders explains the only moderately favorable effects observed in the whole population. We also have to stress that we found very similar effects of corticosteroids in the larger subset of patients who met the criteria for acute lung injury at inclusion (data not shown). Importantly, although the trial was conducted before the publication of the ARDS Network trial demonstrating that a lung-protective strategy with low tidal volume was associated with improved survival in acute lung injury and ARDS, the mean tidal volume of 9 mL/kg of body weight observed in both treatment groups was clearly lower than the values of the ARDS Network trial control group (16) . In fact, observed tidal volumes were closely in keeping with routine practice in European countries in the late 1990s (17) . However, as lower tidal volumes (6 mL/kg) are associated with demonstrated decrease in lung and systemic inflammation (16, 18, 19) , whether low doses of corticosteroids may further attenuate inflammation in patients with such low tidal volumes remains to be evaluated.
The beneficial effects of the steroid therapy observed in the current analysis are in keeping with a previous trial suggesting improved morbidity and mortality in unresolving ARDS with prolonged treatment with low doses methylprednisolone (8) and with a recent trial suggesting decreased morbidity and mortality with 7-day treatment with low doses hydrocortisone in community-acquired pneumonia-induced acute lung injury (20) . These similarities could be expected since, in both the early and late phases of ARDS, it is thought that an imbalance between enhanced cytokine-induced nuclear factor-B activation and reduced glucocorticoid receptor-␣ functional capacity results in excessive local and systemic inflammation (21) . Besides, in patients with unresolving ARDS, methylprednisolone may decrease lung and circulating proinflammatory cytokines levels, restore homeostasis between nuclear factor-B activation and glucocorticoid receptor-␣ signaling pathways, and reduce organ dysfunction severity and duration and hospital mortality rate (22) . Of the blood-borne activators of systemic inflammation, IL-6 may be the most significant. Indeed, its production and release are very sensitive to injury and infection, and its blood concentrations have been shown to be correlated with the severity of inflammation (23) . In our study, IL-6 circulating levels at baseline were clearly higher in nonresponders than in responders, thus probably expressing a higher degree of systemic inflammation and explaining the greater effect of the steroid therapy. However, our data do not allow us to conclude whether these high levels of IL-6 accounted for the observed dysfunction of the hypothalamic-pituitary-adrenal axis or whether the adrenal insufficiency accounted for these high IL-6 levels in nonresponders. Indeed, on one hand, IL-6 has been demonstrated to inhibit the stimulatory effect of corticotropinreleasing hormone on anterior pituitary cells (24) . On the other hand, nonresponders, per definition, cannot increase their cortisol levels in response to additional stress and one may expect to observe sustained and unresolving systemic inflammation (i.e., high IL-6 levels) in these patients. Anyhow, similar favorable effects of low doses of corticosteroids on cytokines levels in septic shock have been reported by others (25, 26) as well as the fact that these effects predominate in nonresponders (27) . Our results are also in keeping with the recent demonstration, in an animal model of early ARDS, that a single low dose of methylprednisolone preserved in vivo and in vitro respiratory mechanics in mild ARDS and attenuated the changes in tissue impedance and extracellular matrix components in severe lesions (27) .
The fact that corticosteroids had no impact on the outcome of septic shock patients without ARDS should not lead to the hypothesis that the benefit from corticosteroids observed in septic shockassociated ARDS was mainly related to the treatment of ARDS and not to the treatment of septic shock. Indeed, the retrospective nature of our analysis and the limited sample size of the subgroup of patients without ARDS do not allow such conclusion.
CONCLUSIONS
This post hoc analysis showed that a 7-day treatment with low doses of corticosteroids was associated with better outcomes in septic shock-associated early ARDS nonresponders but not in responders, and not in septic shock patients without ARDS. These data should prompt the conduction of a multiple-center, placebocontrolled, randomized, double-blind trial to confirm the efficacy and safety of low doses of corticosteroids in patients with early ARDS. Such a study would have to stratify the patients according to their response to corticotropin. 
